UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
ANEBULO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 85-1170950 | |
| (State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) | |
| 1415 Ranch Road 620 South, Suite 201, Lakeway, Texas | 78734 | |
| (Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
| Title
of each class to be so registered |
Name
of each exchange on which each class is to be registered | |
| Common Stock, par value $0.001 per share | The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. [X]
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. [ ]
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. [ ]
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-254979
Securities to be registered pursuant to Section 12(g) of the Act:
| None |
| Title of Class |
| Item 1. | Description of Registrant’s Securities to Be Registered. |
The information required by this Item is included under the captions “Description of Capital Stock” (pages 92 - 95), “ Dividend Policy” (page 48) and “Shares Eligible for Future Sale” (pages 96 - 97) of the Prospectus included as part of the Registrant’s Registration Statement on Form S-1, Registration No. 333-254979 (“Form S-1”), which information is incorporated herein by this reference.
| Item 2. | Exhibits. |
The following documents are included as exhibits to Form S-1, as indicated, and are incorporated herein by this reference:
| 2 |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| ANEBULO PHARMACEUTICALS, INC. | ||
| Dated: May 5, 2021 | By: | /s/ Daniel Schneeberger, M.D. |
| Daniel Schneeberger, M.D. | ||
| Chief Executive Officer | ||
| 3 |
EXHIBIT INDEX
The following documents are included as exhibits to the Registrant’s Registration Statement on Form S-1, Registration No. 333-254979, to be declared effective on May 6, 2021 (“Form S-1”), as indicated, and are incorporated herein by this reference:
| 4 |